Suven Life Sciences reveals breakthrough with Ropanicant in depression treatment
Suven Life Sciences Limited has made a significant advancement in the fight against depression, announcing positive results from a Phase-2a proof-of-concept study involving Ropanicant (SUVN-911). ... Read More
Suven Life Sciences announces positive results from Samelisant Phase-2 study
Suven Life Sciences, a pioneering biopharmaceutical company specializing in Central Nervous System (CNS) disorders, recently announced the successful completion of its Phase-2 proof-of-concept study for ... Read More
Suven Life Sciences set to begin samelisant phase 2 trial in narcolepsy
Suven Life Sciences has announced the successful completion of enrollment for its phase-2 proof-of-concept (PoC) clinical study to evaluate the safety and efficacy of samelisant ... Read More
Suven Life Sciences to launch phase 3 clinical trial for Masupirdine
Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression ... Read More